Pharmacovigilance Agreements (PVA) simplified: key requirements and best practices for compliance
Pharmacovigilance Agreements (PVA) simplified: key requirements and best practices for compliance
Wednesday, 05 March 2025
Soraia Teresa Ferreira Dos Santos, Senior Drug Safety Officer at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
Learn the essentials of Pharmacovigilance Agreements (PVA) and Safety Data Exchange Agreements (SDEA) to ensure regulatory compliance and effective collaboration.
Play
Pharmacovigilance Agreements (PVA): key insights for compliance
AI-generated audio
2:04
Pharmacovigilance Agreements (PVA), also known as Safety Data Exchange Agreements (SDEA), are essential legal contracts that outline the responsibilities for pharmacovigilance activities between two or more parties.
These agreements ensure that Marketing Authorization Holders (MAH) and their partners meet legal obligations, safeguarding compliance and public safety.
In this blog post, we explore when a PVA is required, how it is drafted and managed, the key elements it should include, and its legal basis.
When is a Pharmacovigilance Agreement (PVA) required?
The MAH must establish a PVA in scenarios such as:
-
Outsourcing Pharmacovigilance Activities: When pharmacovigilance tasks are delegated to service providers.
-
Third-Party Involvement: When distribution or manufacturing is performed by external entities.
-
Licensing, Promotion, or Joint Marketing: When collaborating with other parties for these activities.
By formalizing these responsibilities, PVAs ensure seamless coordination and compliance across all stakeholders.
Drafting and managing a Pharmacovigilance Agreement
The development of a Pharmacovigilance Agreements should align with the specific type of business agreement between the involved parties. Key steps include:
-
Separate Drafting: The PVA should be created independently of the overarching business contract to allow updates when necessary.
-
Involvement of the QPPV: The Qualified Person for Pharmacovigilance (QPPV) should participate in drafting or reviewing the agreement to ensure its accuracy and relevance.
-
Robust Implementation: After finalization, the agreement should be implemented through training and documentation to ensure compliance.
-
Updating the PSMF: The Pharmacovigilance System Master File must reflect the details of the PVA to maintain regulatory alignment.
What information should a PVA include?
To be effective, PVAs must be detailed and comprehensive. Key components include:
- Contact Information: Details of the QPPV.
- Responsibilities: Clear delineation of tasks such as:
- Collection and submission of ICSRs (Individual Case Safety Reports).
- Conducting literature searches.
- Writing and submitting periodic safety reports.
- Signal detection and response.
- Handling regulatory authority requests.
- Products and Territories: Specific details about the covered products and their jurisdictions.
- Deadlines: Explicit timelines for data exchanges and responsibilities.
- Review Frequency: Defined intervals for reviewing and updating the agreement.
Legal basis for Pharmacovigilance Agreements
The foundation of PVAs lies in the guidelines provided by Module VI of the Good Pharmacovigilance Practices (GVP). These guidelines cover:
-
Data Collection and Management: Processes for handling suspected adverse reactions.
-
Reporting Requirements: Obligations for both serious and non-serious adverse reactions for medicinal products in the EU.
For detailed guidance, refer to GVP Module VI.
Why choose QbD Group for PVA support?
QbD Group specializes in drafting and managing Pharmacovigilance Agreements. Our experts bring extensive experience to ensure your PVAs are comprehensive, compliant, and tailored to your needs. We provide:
- expert guidance on drafting PVAs.
- comprehensive solutions for implementation and compliance.
- ongoing support to anticipate and meet regulatory requirements.
If you need advice or assistance with your Pharmacovigilance Agreements, contact QbD Group today to ensure your organization’s compliance and collaboration success.
Need post-market vigilance support?
Our Global Safety Solutions supports your products post-market with vigilance, safety, and compliance.
Explore our solutions.
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Discover more expert content
Webinar
Scaling Pharmacovigilance in Europe: A Practical Guide for Pharma SMEs and Biotechs
This webinar on demand will provide clear, experience-based guidance on how to manage pharmacovigilance (PV) across Europe without overextending your resources. You’ll learn how to balance global consistency with country-specific requirements, meet strict European timelines with lean teams, and apply practical, proven strategies that strengthen both central oversight and local execution.
Webinar
Pharmacovigilance and Risk Management in Innovative Therapies: A Challenge in Drug Safety
Explore pharmacovigilance in cell, CAR T, and RNA therapies. Join our webinar to tackle tomorrow’s drug safety and risk management challenges.
.jpg)
Webinar
Unlocking Strategic Value in Drug Safety for Life Sciences Organizations
Explore how drug safety teams can transform into proactive benefit drivers with the right tools & resources in this webinar on demand.
Whitepaper
The One-Vigilance strategic roadmap to corporate excellence
This whitepaper introduces the concept of One Vigilance within the context of the current drug safety landscape. Download now.
Whitepaper
Ensuring compliance and quality in Pharmacovigilance
The whitepaper emphasizes the importance of a robust pharmacovigilance QMS and a well-maintained Pharmacovigilance System Master File (PSMF). Download now.
Case study
Optimizing pharmacovigilance for a biotechnology leader
Discover how QbD Group improved pharmacovigilance for a global leader in biotechnology, ensuring regulatory compliance and patient safety.
Case study
Revolutionizing pharmacovigilance: a success story of strategic partnership and seamless integration
Discover how QbD Group's expert support enhanced a pharmaceutical company's pharmacovigilance, leading to a favorable inspection outcome by the local Regulatory Authority (AEMPS).
.jpg)
Case study
Patient Support Program (PSP)
Learn about our patient support program (PSP) and how it helps manage customer support for a PV Spanish client. Resolve quality issues and ensure stability with QbD Pharma.
Twitter Widget Iframe